Resource allocation for different types of vaccines against COVID-19: Tradeoffs and synergies between efficacy and reach
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
-
SciScore for 10.1101/2021.01.28.21250713: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:We also acknowledge some limitations of this study. First, our modified SIR-D model does not fully capture the potential trajectory of an infectious disease over its lifetime. There could be additional stages (compartments), such as asymptomatic infected individuals who spread the disease with a different transmission rate or symptomatic …
SciScore for 10.1101/2021.01.28.21250713: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:We also acknowledge some limitations of this study. First, our modified SIR-D model does not fully capture the potential trajectory of an infectious disease over its lifetime. There could be additional stages (compartments), such as asymptomatic infected individuals who spread the disease with a different transmission rate or symptomatic infected individuals who are either quarantined or hospitalized such that they no longer spread the virus. Second, implementation of non-pharmaceutical interventions often separates conforming individuals from the susceptible population temporarily. Individuals who decide to stop conforming to the interventions may re-enter the susceptible populations during a pandemic, as considered in [22]. Third, a virus may mutate and change the reproduction number over time. Fourth, while we assume a homogeneous population, each individual may show different characteristics to build antibodies when vaccinated or to recover from the virus, depending on factors such as demographics. Fifth, we model all vaccinations in an immediate deployment rather than a phased rollout. Even if one receives an effective vaccine, it may still take several days to fully build antibodies and fight off the infection. Lastly, our model assumes that both vaccine types require a single dose. Most of the current vaccine candidates against COVID-19, both mRNA-based and adenovirus-vector-based, require two doses with three to four weeks apart application to provide the most protect...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-